PROJECT

Projects

Environmental & Social Review Summary

Project Number

35027

Company Name

JUBILANT PHARMA LIMITED

Date ESRS Disclosed

May 29, 2014

Country

India

Region

South Asia

Last Updated Date

Jun 12, 2021

Environmental Category

B - Limited

Status

Completed

Previous Events

Approved : May 9, 2014
Signed : May 15, 2014
Invested : May 23, 2014

Sector

Pharmaceuticals and Medicine

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

JPL’s manufacturing facilities in India include 2 facilities, i.e. (a) Nanjangud manufacturing APIs and (b) Roorkee manufacturing generics (tablets and capsules). In addition, the North American facilities, i.e. 2 facilities in United States of America (in Salisbury, Maryland and Spokane, Washington) and 1 in Canada (Kirkland, Quebec) are part of the pharmaceuticals business. The North American facilities manufacture ointments, creams and liquids (OCLs), sterile injectable, allergy therapy, generics (tablets and capsules), and radiopharmaceuticals.

As indicated above, JPL is a fully owned subsidiary of JLS, which is a part of an Indian conglomerate Jubilant Bhartia Group (“JBG” or “the Group”). Headquartered in Noida (Uttar Pradesh) near Delhi, the Group has presence in diverse sectors, in addition to Pharmaceuticals and Life Science Ingredients (LSI), which include Food (Jubilant Food works), Agri & Performance Polymers (Jubilant Industries Limited), Oil & Gas (Jubilant Energy), Retail (Jubilant Retail), Auto (Jubilant Motor works), and Consulting Services in Aerospace & Oilfield industries (Jubilant Enpro).

The proposed investment involves an overall IFC arranged financing package (“the Project”) in a combination of quasi equity and debt (including mobilization) to allow JLS to finance the transfer of its Indian pharmaceutical operating assets to JPL and thus consolidate its overall pharmaceutical business under JPL. In the process, the proposed transfer of the Indian assets to Jubilant Generics Ltd (JGL), incorporated in India as a subsidiary of JPL, will enable JLS to decouple fully its chemicals and pharmaceutical businesses for the primary purpose of creating more shareholder value through an offshore listing of JPL once the consolidation is in place. There will not be physical relocation of the production facilities.

Overview of IFC's Scope of Review

Considering the nature of the proposed investment (i.e. a corporate investment) in Jubilant Pharma Limited (“JPL” or “the company”), a fully owned subsidiary of Jubilant Life Sciences (JLS), the focus of the IFC review was to understand capacity, maturity, and reliability of the corporate environmental and social (E&S) management systems to effectively manage E&S performance, specifically for the pharmaceutical business assets and operations, including their ability to ensure current and ongoing compliance with IFC’s Performance Standards. To understand typical E&S risks and impacts associated with the pharmaceutical manufacturing operations which will need to be managed, the E&S performance of existing operations and assets in India was also reviewed during the visit.

Based on the above approach, IFC’s review of this investment consisted of appraising information related to technical, environmental, health and safety (EHS) and social matters including: business details, corporate policies and procedures on EHS, Climate Change Mitigation and Green Supply Chain, management system information, regulatory permits, Human Resources (HR) records, organization charts, environmental monitoring reports, safety audits, on-site/off-site emergency response plans, and other EHS related studies completed for the operating facilities. The appraisal included site visits to the Active Pharmaceuticals Ingredients’ (APIs) facility in India, located at Nanjangud (Karnataka state) and the Formulation facility at Roorkee (Uttarakhand state) and discussions with corporate senior management and facility management, Chief Sustainability Officer and sustainability and EHS teams both at the corporate and facilities level.

IFC’s review considered company’s management of its EHS risks and impacts in the operation of its existing pharmaceutical facilities and environmental and social management plans for the Project and gaps, if any, between these plans and IFC requirements. Measures included in the management plans and, where necessary, corrective measures intended to close these gaps within a reasonable period of time, are summarized in the paragraphs that follow and in the agreed Environmental and Social Action Plan (ESAP) disclosed in this review summary. Through implementation of these management plans and the ESAP the Project is expected to be designed and operated in accordance with Performance Standards objectives.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan